Needle

JHP Pharmaceuticals acquired by Warburg Pincus

JHP Pharmaceuticals, a pharmaceutical company that acquires, develops, manufactures and sells sterile injectable products, has been acquired by an affiliate of private equity firm Warburg Pincus.

The company was acquired from JHP Holdings, an entity majority-owned by Morgan Stanley Principal Investments, for USD195m on a debt-free, cash-free basis. 

JHP's current management team will continue to hold an interest in the company.

Since its founding in 2007, JHP has developed into a leading specialty pharmaceutical company focused on the USD30bn US sterile injectable drug market. JHP's market presence, high-quality sterile manufacturing facility, and experienced management team, coupled with growth capital and support from Warburg Pincus, will enable the company to pursue unique partnership and acquisition opportunities in both the branded and generic segments of the sterile injectable market.

"Over the past five years, JHP has established itself as a strong injectable pharmaceutical business manufacturing and marketing its own branded and generic products, developing a strong generic products pipeline, and supporting other pharmaceutical companies in the development and manufacturing of innovative products," says Stuart Hinchen, co-founder and chief executive of JHP. "In 2013, we will launch the first products from our strong pipeline of generic products. We believe Warburg Pincus is an ideal partner for JHP's growth and expansion in the coming years. Warburg Pincus has deep experience in healthcare and pharmaceuticals in particular and is well known for its proven ability to strengthen the platforms of its portfolio companies."

"We have been impressed with the financial performance and quality record of JHP over the last five years, and are very pleased to contribute to the further development of the company," says Elizabeth H Weatherman, managing director and head of the healthcare group, Warburg Pincus. "The management team has done an excellent job building the company and we are delighted they are remaining with the business and co-investing.   JHP represents an attractive investment opportunity for us and we have reserved a sizeable amount of additional capital to fund growth opportunities that will transform the business well beyond what it is today."

Further reading



Upcoming events

1 day 17 hours from now - Amsterdam
2 days 17 hours from now - London
1 week 2 days from now - London
1 week 2 days from now - London
1 week 2 days from now - Cartegena

Upcoming training